Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →King CEO Brian Markison: "the combination of these two companies' strong and complementary business models, we will create the nation's leading diversified…
"Mylan Laboratories Inc. and King Pharmaceuticals, Inc. today announced that the companies have mutually agreed to terminate the agreement... Following…
Icahn called the collapse 'a victory for all Mylan shareholders and a victory for shareholder activism in general,' having previously labeled the deal 'stupid'…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Stock-for-stock; 0.9 Mylan shares per King share; $16.659/King share; deal terminated February 2005
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Laboratories Inc. / King Pharmaceuticals Inc. (this deal) | 2004 | $4.0B | — |
| Mylan Laboratories Inc. / Merck Generics (Merck KGaA) | 2007 | $6.7B | 81 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2006 | $736M | 66 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2005 | $736M | 39 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2004 | $7.6B | 84 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |